C12Y 302/01018
Exo-alpha-sialidase , i.e. trans-sialidase
Official title: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
C12Y302/01018 (Exo-alpha-sialidase , i.e. trans-sialidase) appears on 186 US grants and 287 published applications in this corpus.
Search patents in C12Y- Granted patents
- 186
- Published applications
- 287
- Assignees
- 164
- Inventors
- 488
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 9 | 0 |
| 2000 | 6 | 0 |
| 2001 | 4 | 1 |
| 2002 | 2 | 5 |
| 2003 | 3 | 4 |
| 2004 | 2 | 4 |
| 2005 | 2 | 4 |
| 2006 | 3 | 3 |
| 2007 | 3 | 5 |
| 2008 | 2 | 1 |
| 2009 | 1 | 8 |
| 2010 | 4 | 10 |
| 2011 | 5 | 9 |
| 2012 | 7 | 13 |
| 2013 | 7 | 11 |
| 2014 | 5 | 14 |
| 2015 | 13 | 18 |
| 2016 | 8 | 15 |
| 2017 | 8 | 16 |
| 2018 | 11 | 14 |
| 2019 | 8 | 22 |
| 2020 | 12 | 22 |
| 2021 | 8 | 10 |
| 2022 | 6 | 18 |
| 2023 | 2 | 13 |
| 2024 | 5 | 20 |
| 2025 | 4 | 11 |
| 2026 | 11 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Method for prevention and treatment of viral disease25 Aug 2026US 12,714,746 B2Morehouse School of Medicine
- Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof14 Jul 2026US 12,680,085 B2The University of Hong Kong
- Recombinant neuraminidase and uses thereof16 Jun 2026US 12,655,408 B2Icahn School of Medicine at Mount Sinai
- Biosensors for selectively identifying azide ions16 Jun 2026US 12,655,461 B2Rutgers, The State University of New Jersey
- Chimeric polypeptides, extracellular vesicles comprising the same, and uses thereof1 Oct 2026US 2026/0295068 A1Ciloa
- Recombinant neuraminidase and uses thereof17 Sep 2026US 2026/0275315 A1Icahn School of Medicine at Mount Sinai
- Method for prevention and treatment of viral disease10 Sep 2026US 2026/0265719 A1Morehouse School of Medicine
- Conjugates for Targeted Cell Surface Editing3 Sep 2026US 2026/0258150 A1The Board of Trustees of the Leland Stanford Junior University
- Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors3 Sep 2026US 2026/0258355 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Recombinant negative strand RNA virus expression systems and vaccines171US 5,854,037 AMount Sinai School of Medicine of the City University of New York · 1998
- Recombinant negative strand RNA virus expression systems and vaccines118US 5,820,871 AMount Sinai School of Medicine of the City University of New York · 1998
- Production of lysosomal enzymes in plant-based expression systems117US 5,929,304 ACroptech Development Corporation · 1999
- Method of controlling the degradation of glycoprotein oligosaccharides produced by cultured Chinese hamster ovary cells96US 5,510,261 AThe Board of Trustees of the Leland Stanford Juniot University · 1996